Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RCKT) | Delayed: 2.22 -0.09 (3.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.31 | 52 Week High | $ | |||
| Open | $2.27 | 52 Week Low | $ | |||
| Day High | $2.28 | P/E | N/A | |||
| Day Low | $2.17 | EPS | $ | |||
| Volume | 788,316 | |||||
